Axitinib (off Label)
Observation
none · ITT
R/M ACC with progression within 9 months
median overall survival: 27.2 months, axitinib median not reached; P 0.226
Axitinib vs observation (randomized Phase 2) · NCT02859012
ACC
Programs, trials, and reported response and survival for adenoid cystic carcinoma.
ACC pipeline
Each card is one trial arm. A bar is a response percent the source states. Progression-free survival, overall survival, and a hazard ratio stay in the units the source used. This page does not subtract one arm from another.
5 arms have a reported figure in this set.
Observation
none · ITT
R/M ACC with progression within 9 months
median overall survival: 27.2 months, axitinib median not reached; P 0.226
Axitinib vs observation (randomized Phase 2) · NCT02859012
Axitinib + avelumab
axitinib 5 mg twice daily + avelumab · Single arm
R/M ACC (n = 28 evaluable)
median overall survival: 16.6 months, primary analysis
Lenvatinib 24 mg
24 mg · Single arm
R/M salivary ACC (n = 26 evaluable)
median overall survival: 27 months, primary analysis
ACC-LEN14 · NCT02860936
AL101 4 mg
4 mg · Single arm
R/M ACC with NOTCH1 to 4 activating mutation (n = 45)
median overall survival: 9.3 months, final
ACCURACY · NCT03691207
AL101 6 mg
6 mg · Single arm
R/M ACC with NOTCH activating mutation (n = 42)
median overall survival: 9.4 months, final
ACCURACY · NCT03691207
A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.